Cedars-Sinai investigators have discovered that large oncosomes—fluid-filled sacs released into the bloodstream by aggressive ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory ...

The incidence of neuroendocrine tumors is increasing, necessitating the need for more post-operative medical strategies. Available therapies and promising agents are discussed in this article.

Exelixis stock shines with 36% CABOMETYX sales growth, promising zanzalintinib market expansions, and raised 2025 guidance.

Bruna was subsequently prescribed antidepressants, but despite her condition steadily worsening, her concerns were repeatedly ...

A student has shared her experience of being repeatedly dismissed by doctors, despite losing 10 kilos in just two months and ...

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma ...

Large cell neuroendocrine carcinoma of the prostate is an extremely rare malignant subgroup with limited reported cases. Little is known about its pathological characteristics, treatment options and ...

Boehringer Ingelheim shares how it is addressing healthcare inequalities in cancer care, with a particular emphasis on ...

Organ-sculpting cells may hold clues to how cancer spreads by University of North Carolina at Chapel Hill edited by Stephanie Baum, reviewed by Robert Egan Editors' notes ...

SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer ...

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...